Similar Articles
341 Ablative strategies for recurrent hepatocellular carcinoma
342 Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States
343 Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges
344 Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
345 Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma
346 Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
347 Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
348 Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics
349 Hepatocellular carcinoma: State of the art diagnostic imaging
350 Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA